O1‐06‐05: First‐in‐human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta‐amyloid levels after single dosing-Reference-Cited by-同舟云学术

O1‐06‐05: First‐in‐human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta‐amyloid levels after single dosing

Published:2012-07 Issue:4S_Part_3 Volume:8 Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Lai Robert¹,Albala Bruce²,Kaplow June M.²,Aluri Jagadeesh²,Yen Mark³,Satlin Andrew²

Affiliation:

1. Eisai Ltd.HatfieldUnited Kingdom

2. Eisai Inc.Woodcliff LakeNew JerseyUnited States

3. ParexelGlendaleCaliforniaUnited States

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2012.05.237

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery;Pharmaceutics;2023-04-03

2. Small-molecule drugs development for Alzheimer's disease;Frontiers in Aging Neuroscience;2022-11-01

3. Novel 3-aminobenzofuran derivatives as multifunctional agents for the treatment of Alzheimer’s disease;Frontiers in Chemistry;2022-08-09

4. Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers;International Journal of Molecular Sciences;2020-11-17

5. In Silico Inhibition of BACE-1 by Selective Phytochemicals as Novel Potential Inhibitors: Molecular Docking and DFT Studies;Current Drug Discovery Technologies;2020-07-15